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Abstract

TYPE-5 PHOSPHODIESTERASE INHIBITION IN PREVENTION OF DOXORUBICIN
CARDIOMYOPATHY
By Patrick William Fisher, DO, PhD
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy in Physiology at Virginia Commonwealth University.
Virginia Commonwealth University, 2005
Major Director: Rakesh C. Kukreja, PhD
The Eric Lippman Chair of Molecular Cardiology
Department of Medicine
Division of Cardiology

Prior studies have demonstrated the effect of diazoxide in protecting against apoptosis via
mitochondrial KATP channel opening in vitro. The current investigations are designed to
determine if sildenafil, a phosphodiesterase-5 inhibitor and known mitochondrial KATP
channel opener, would protect against chronic doxorubicin cardiomyopathy both in vivo
and in vitro.

xv

xvi
Male ICR mice were randomized to 1 of 4 treatments: saline, sildenafil (0.7 mg/kg IP),
doxorubicin (5 mg/kg IP), and sildenafil (0.7 mg/kg IP)+doxorubicin. Apoptosis was
determined using the terminal deoxynucleotidyl transferase–mediated dUTP nick-end
labeling and in situ oligo ligation methods. Desmin distribution was determined via
immunofluorescence. Bcl-2 was analyzed by Western blot. Left ventricular function was
measured in Langendorff mode. Electrocardiographical analysis measured changes
indicative of doxorubicin cardiotoxicity (ST-prolongation). In vitro studies using adult
ventricular cardiomyocytes were exposed to doxorubicin (1 µM), sildenafil (1 µM) with or
without NG-nitro-L-arginine methyl ester (L-NAME; 100 µM)), or 5-hydroxydecanoate (5HD; 100 µM)) 1 hour before doxorubicin and incubated for 18 hours.

Doxorubicin-treated mice demonstrated increased apoptosis and desmin disruption, which
was attenuated in the sildenafil+doxorubicin group. Bcl-2 decreased in the doxorubicin
group but was maintained at basal levels in the sildenafil+doxorubicin group. Left
ventricular developed pressure and rate pressure product were significantly depressed in
the doxorubicin group but attenuated in the sildenafil+doxorubicin group. ST-interval
significantly increased in the doxorubicin group over 8 weeks. In the
sildenafil+doxorubicin group, ST-interval remained unchanged from baseline. Doxorubicin
significantly increased apoptosis, caspase-3 activation, and disruption of mitochondrial
membrane potential in vitro. In contrast, sildenafil significantly protected against
doxorubicin cardiotoxicity; however, protection was abolished by both L-NAME and 5HD. Cell viability studies using spectrophotometer and flow cytometric techniques

xvii
demonstrated that sildenafil did not affect the antitumor efficacy of doxorubicin in PC-3
cells in vitro. In fact, flow cytometry data indicate that sildenafil, when combined with
doxorubicin, was synergistic in the antineoplastic action of doxorubicin.

Prophylactic treatment with sildenafil prevented apoptosis and left ventricular dysfunction
in a chronic model of doxorubicin-induced cardiomyopathy. Moreover, these studies
provide relevant clinical data on the safety and efficacy of sildenafil, leading the way for
clinical trials in humans receiving doxorubicin chemotherapy.

BACKGROUND

Heart failure remains a leading cause of morbidity and mortality in the United States,
affecting approximately 5 million Americans; particularly those age 65 and older. In
1995, Medicare spent an estimated $3.4 billion dollars for the treatment of heart failure.
In 2004, this number increased to $28 billion dollars. A continually aging population is
expected to result in a greater number of people afflicted with heart failure, requiring
costly long-term medical management with unpredictable effect on quality of life [1].

Etiologies of heart failure development are numerous and involve complex molecular
mechanisms, not entirely understood. However, recent advances have expanded our
knowledge and understanding of the cellular and molecular mechanisms involved in the
development of heart failure. For example, progress in primary and secondary prevention
of coronary artery disease has improved the ability of physicians to target at-risk
populations who may benefit from early treatment and lifestyle modifications aimed at
reducing myocardial infarction and the development of ischemic cardiomyopathy. In
contrast, prevention of nonischemic cardiomyopathy remains a challenge. Moreover,
successful treatment is often palliative unless the patient is able to receive an orthotopic
heart transplant. Left ventricular assist devices offer promise as a bridge to
1
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transplantation or as destination therapy. However, despite these modern biomedical
innovations, a cure is not attainable and both life expectancy and quality of life are
unpredictable.

Over thirty years ago, the introduction of the anthracycline antibiotics markedly shifted
the momentum in the battle against cancer. Doxorubicin, one of the most widely used
anthracyclines, continues to be a powerful weapon in the treatment of many human
neoplasms, including Kaposi’s Sarcoma, acute leukemias, lymphomas, stomach, breast,
and ovarian cancers [2]. Despite its clinical efficacy, doxorubicin is associated with a
delayed and progressive cardiomyopathy often presenting more than 20 years after
treatment cessation [3,4,11]. The underlying mechanism of chronic doxorubicin-induced
cardiomyopathy occurs primarily via the generation of reactive oxygen species (ROS) in
the cardiomyocyte mitochondria—a mechanism that is separate from its antineoplastic
activity, which occurs primarily through inhibition of topoisomerase II [5]. Additionally,
numerous studies involving both in vitro and in vivo models of heart failure link ROS to
cardiomyocyte apoptosis [6-9]. In fact, it is hypothesized that apoptosis plays a role in
the development of heart failure via mechanisms that contribute to cardiomyocyte loss,
eventually leading to structural changes maladaptive to normal cardiac physiological
demands [10]. Over the past three decades, significant research has focused on
unraveling this conundrum. More recently, a prospective study evaluating cardiac
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abnormalities in childhood survivors of cancer 15 years or more after treatment with
doxorubicin, demonstrated an increased incidence of cardiomyopathy at doses much
lower than the current acceptable total cumulative dose of approximately 450 mg/m2
[11,12]. In fact, the prevalence of severe cardiac dysfunction was found in more than six
percent of patients at 15 years post-treatment at doses less than 250 mg/m2. Moreover,
the mean prevalence of severe cardiac dysfunction in patients receiving more than 250
mg/m2 was found to be 19% at 25 years after treatment. Overall, after an average
follow-up of 18 years, 39% of childhood cancer survivors treated with doxorubicin
exhibited severe cardiac dysfunction. Additionally, severe cardiac dysfunction was
identified in 6% of patients who had no prior clinical history of cardiac failure with doses
of doxorubicin at or above 150 mg/m2 without evidence for threshold. [11]

Despite advances in understanding this disease process at the cellular and molecular
level, prophylactic pharmacological agents are lacking. Because of the potency, broad
spectrum, and efficacy of doxorubicin in treating many malignancies today, coupled with
the difficulty in treating patients with doxorubicin-induced cardiomyopathy, it is
imperative that the development of novel approaches aimed at prevention of
cardiotoxicity is aggressively pursued. The ideal agent must prevent cardiotoxicity while
maintaining effective anti-neoplastic activity

PHARMACOLOGY OF DOXORUBICIN

Mechanism
Doxorubicin is an anthracycline antibiotic, isolated from Streptomyces peucetius var
caesius. There are three major actions that account for the anti-neoplastic activity and
toxicity of doxorubicin: (1) high affinity DNA binding via intercalation and interaction
with topoisomerase II, ultimately blocking the synthesis of both DNA and RNA; (2)
binding to cellular membranes with alteration of fluidity and ion transport; and (3) redox
cycling of doxorubicin to its semiquinone free radical with subsequent generation of
oxygen radicals. Additionally, several hypotheses have been proposed to explain the
acute and chronic cardiotoxicity of doxorubicin; these include formation of free radicals,
inhibition of enzymes and proteins, changes in cardiac muscle gene expression,
alterations of mitochondrial membrane function, sensitization of Ca2+ release from
sarcoplasmic reticulum channels, mitochondrial DNA damage, and dysfunction. [1215,58]

It is thought that doxorubicin alone is responsible for acute cardiotoxicity. In contrast,
chronic cardiotoxicity is believed to be a result of chronic, perpetual redox cycling of
doxorubicin in the mitochondria—a process that continues long after serum
concentrations become undetectable.
4
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Pharmacokinetics
In the clinical setting, doxorubicin is administered by intravenous (IV) injection. The
usual dose is 60 mg/m2 IV every three weeks to a maximum dose of 450-550 mg/m2.
However, smaller, more frequent doses (once per week) are commonly used depending
on type of malignancy, overall chemotherapeutic regimen, prior history of anthracycline
exposure, and cardiac risk factors. After IV administration, peak serum concentrations of
doxorubicin are attained rapidly. Thirty minutes after infusion, serum concentration
drops by approximately 50%. However, significant levels persist for up to 20 hours. The
main route for doxorubicin metabolism is via the liver where it undergoes reduction and
hydrolysis of ring substituents. The alcohol metabolite of doxorubicin, doxorubicinol, is
pharmacologically active. In contrast, the aglycone derivative is an inactive metabolite.
The majority of doxorubicin and its metabolites are excreted in the bile with a minute
amount excreted in the urine. Enterohepatic recirculation of toxic metabolites occurs
during biliary excretion. Therefore, dose reduction needs to be considered in patients
with hepatic disease or elevated hepatic transaminases. [16]

CELLULAR AND MOLECULAR MECHANISMS OF DOXORUBICIN
CARDIOTOXICITY
Multiple studies substantiate the major role that reactive oxygen species (ROS) play in
the development of heart failure both in vivo and in vitro [17,18]. In fact, substantial
evidence exists implicating the generation of ROS as the underlying mechanism for the
development of dilated cardiomyopathy and heart failure from multiple etiologies
including chemotherapy-induced [14,17,18]. Moreover, prior studies have identified the
mitochondria as the main target of doxorubicin accumulation in cardiac cells [19]. In
fact, mitochondrial concentrations of doxorubicin (5-50 uM) are several-fold greater than
simultaneous clinically relevant serum concentrations (0.1-1 uM) [20].
Mitochondrial NADH dehydrogenase is a major contributor to doxorubicin-generated
reactive oxygen species (ROS) production via redox cycling of doxorubicin to its
semiquinone [21, Figure 1].

Figure 1A. Redox cycling of doxorubicin
& formation of Superoxide.
# 2005 Patrick William Fisher, DO, PhD
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NO

Figure 1B. Redox cycling of doxorubicin and formation of ROS & RNS.
# 2005 Patrick W. Fisher, DO, PhD

It is therefore, not surprising that high mitochondrial concentrations of doxorubicin,
relative to simultaneous serum concentrations, rapidly perpetuates the formation of free
radicals. Compared with other organs such as the liver, the heart possesses a relatively
limited supply of catalase and glutathione peroxidase (GSH-Px), key intracellular free
radical scavengers. Because of chronic doxorubicin free radical production in the heart,
the supply of both GSH-Px and catalase is rapidly expended; thus, creating an
environment that promotes hydroxyl radical production [22].

8

Accordingly, the accumulation of ROS results in dissipation of the mitochondrial
membrane potential (!"m), direct activation of the mitochondrial permeability transition
pore (MPTP), and release of cytochrome-c with subsequent activation of caspase-9 and
caspase-3 followed by DNA fragmentation consistent with apoptosis [34].

Figure 2. Cell signaling pathways involved in doxorubicin-induced cardiotoxicity.
# 2005 Patrick W. Fisher, DO, PhD

APOPTOSIS
It is well known that doxorubicin-induced cardiomyocyte apoptosis occurs via both the
extrinsic and intrinsic pathways [23,24]. However, it remains unknown whether one
pathway is more important than the other in respect to doxorubicin-induced cardiomyocyte
apoptosis. However, recent studies substantiate the significance of the intrinsic pathway of
apoptosis in this pathophysiological process [25,26].

Apoptosis, commonly known as programmed cell death, is a regulated cellular process
dependent on ATP [27]. It results in cell death for reasons that often are required in
maintaining normal physiological function in many species. For example, apoptosis plays
an important role in the degeneration of the human thymus gland. Additionally, apoptosis
is critical in sloughing of intestinal epithelial tissue, which rapidly turns over multiple
times a year in humans [28]. Distinguishing apoptotic cell death from necrotic cell death
and DNA repair mechanisms has remained controversial [29]. However, it is now possible
to delineate these two very different modes of cell death through the implementation of
several sensitive and specific assays. The most well defined method for determining
apoptosis from necrosis is by morphological evaluation [30]. Apoptosis is recognized by a
series of well-defined morphological changes that differ from necrotic cell death [31]. In
apoptosis, common morphological findings include condensed heterochromatin often
observed in the perinuclear regions of the cardiomyocyte, cell shrinkage, nuclear pyknosis,
and late fragmentation into apoptotic bodies [31]. In contrast, necrotic cell death is

9
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characterized by cell membrane disruption and release of intracellular contents that are
toxic to surrounding cells and tissues [31].

Apoptosis contributes to the development of heart failure via mechanisms that contribute
to a loss of cardiomyocytes over time, leading to structural changes that often are
maladaptive to normal cardiac physiological demands [6,10]. Furthermore, it is also
suggested that the major difference between whether cells undergo apoptosis versus
necrosis is the cellular availability of ATP [32]. Since apoptosis is an energy dependent
process requiring ATP, cells originally destined for programmed cell death may undergo
necrotic cell death if depleted of adequate ATP stores [32].
Extrinsic Pathway of Apoptosis [Figure 3]
The extrinsic pathway is initiated via binding of a death ligand to a cell surface receptor.
The ligand is usually one of two different types. The Fas ligand (Fas-L), otherwise known
as CD95 or Apo-1, is an integral membrane protein found on the surface of another cell (TLymphocyte). On the other hand, a ligand may exist as an extracellular protein such as
tumor necrosis factor-alpha (TNF-$). Upon ligand-receptor binding, the death-inducing
signaling complex (DISC) is formed. For example, the binding of Fas-L to the Fas
receptor results in recruitment of the Fas-associated death domain (FADD). Consequently,
the recruitment of caspase-8 by FADD results in cleavage of the procaspase to its active
form. Activated caspase-8 can directly activate caspase-3 while completely bypassing the
mitochondrial death pathway. However, active caspase-8 can also activate the BH3
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interacting death domain agonist (Bid), a proapoptotic Bcl-2 (B cell leukemia/lymphoma2) protein, which links the extrinsic to the intrinsic pathway of apoptosis. Both in vivo and
in vitro studies of acute doxorubicin cardiotoxicity have demonstrated involvement of both
TNF-alpha and FAS/FAS-L in this process. [33,34, Figure 3]

Figure 3. Simplified Version of the Entrinsic Pathway of Apoptosis in Doxorubicin
Cardiotoxicity and the Illustration of the Key Link Betweeen Extrinsic and Intrinsic
Pathways. # 2005 Patrick W. Fisher, DO, PhD
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Intrinsic Pathway of Apoptosis [Figure 4]
The intrinsic pathway of apoptosis is more complex than the extrinsic pathway and is
stimulated by a multitude of various extracellular stimuli and intracellular signaling
mechanisms [33,36]. Extracellular stimuli include growth-factor withdrawal or complete
deficit of trophic factors or nutrients, ionizing radiation, and chemicals such as toxins.
Intracellular stimuli include oxidative stress, DNA damage, physical stress on the cytosolic
matrix proteins that provide a support or scaffold for cells such as myocytes, or oxidation
of fatty acids. The result of activation of the intrinsic pathway of apoptosis is the release
of pro-apoptotic proteins, such as cytochrome-c and apoptosis-inducing factor (AIF), into
the cytosol with activation of caspases and subsequent DNA fragmentation [36].
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Figure 4. Simplified Illustration of the Intrinsic Pathway of Apoptosis in Doxorubicin
Cardiotoxicity. # 2005 Patrick W. Fisher, DO, PhD

KEY MEDIATORS OF APOPTOSIS

Caspases
Caspases belong to the class of cysteine proteases that cleave substrates after aspartic acid
residues. They play a critical role in apoptosis. Moreover, caspases are synthesized as
inactive zymogens known as procaspases. Procaspases contain an N-terminal prodomain
and a C-terminal catalytic domain. The catalytic domain consists of a 20 kDa (p20) and a
10 kDa (p10) subdomain. Caspases can further be divided into upstream versus
downstream caspases. Upstream caspases include caspases 2, 8, 9, 10, and 12.
Downstream caspases include caspases 3, 6, and 7. These caspases are then converted to
their respective active forms by proteolytic cleavage after aspartic acid residues, located
between the prodomain, p20, and p10 subunits. Caspase-3 is a key effector in the
apoptotic pathway, amplifying the signal from initiator caspases (such as caspase-8) and
signifying full commitment to cellular disassembly. In addition to cleaving other caspases
in the enzyme cascade, caspase-3 has been shown to cleave poly (ADP-ribose) polymerase
(PARP), DNA-dependent protein kinase, protein kinase C!, actin, and intermediate
filaments such as desmin. Caspase-8 plays a critical role in the early cascade of apoptosis,
acting as an initiator of caspase activation; whereas, caspase-9 is an integral component of
the intrinsic pathway of apoptosis where it cleaves procaspase-3 to its active form. [35,37]

22
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Figure 5. Illustration of caspase-3 and associated subunits.
# 2005 National Library of Medicine.

In addition, the cleavage of the pro-caspase to its active form has long been regarded as an
irreversible marker of commitment to apoptotic cell death. However, more recent studies
have demonstrated the ability of NO, at physiological concentrations, to directly, but
reversibly, inactivate caspase-3 (activated cleaved form) via s-nitrosylation at the cysteine
residue on the p17 subunit [68,71].
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Bcl-2 Family of Proapoptotic and Antiapoptotic Proteins
Bcl-2 is a key regulator of apoptosis and is essential for proper development, tissue
homeostasis, and elimination of exogenous toxic stimuli. Bcl-2 is a 26 kDa, anti-apoptotic
protein, which promotes cell survival via interactions with anti-apoptotic Bcl-2 family
members. These include Bax, Bak, Bik, Bad, and Bid. One of the major functions of Bcl2 is prevention of cell death through its ability in blocking the release of cytochrome-c
from the intramembrane space of the mitochondria. Bax and Bak are multidomain
proapoptotic Bcl-2 proteins. Either Bax or Bak is required for all instances of apoptosis
mediated via the intrinsic pathway. Their interaction at the mitochondrial membrane
contact site contributes to the formation of the voltage-dependent anion channel, or
VDAC—facilitating the release of cytochrome-c to the cytosol. [38-41]

Cytochrome-c
Cytochrome-c is an electron transport protein essential in aerobic energy conversion. It is
found in the mitochondrial intermembrane space in mammalian species. Cytosolic
cytochrome-c is a key mediator in the intrinsic pathway of apoptosis. For example, the
release of cytochrome-c to the cytosol results in the formation of the apoptosome and
activation of downstream caspase-3; consequently leading to interaction of activated
caspase-3 with nuclear dsDNA resulting in DNA fragmentation characteristic of apoptosis
[38,41].

17

Mitochondrial membrane potential ("m) & Mitochondrial KATP Channels
The collapse of "%m is a prominent feature of apoptosis, representing an irreversible
marker of cellular commitment to apoptotic cell death [42]. Moreover, breakdown of the
mitochondrial membrane potential (""m) may precede nuclear signs of apoptosis, and it
may be associated with Ca2+ homeostasis.
Prior research using the mitoKATP channel opener, diazoxide, demonstrated a link between
mitoKATP channel opening and preservation of mitochondrial integrity, maintenance of
mitochondrial membrane potential, and inhibition of cytochrome-c translocation to the
cytosol following in vitro oxidative stress [43]. Moreover, the opening of mitoKATP
channels is critical in mediating the cardioprotective effect induced by pathophysiological
stressors and pharmacological agents. The activation of these channels is triggered by a
drop in tissue ATP levels, which result in preventing the dissipation of the mitochondrial
membrane potential and inhibition of apoptosis [43,44].
Furthermore, studies by Marban et al have shown that opening of mitochondrial KATP
channels by diazoxide induced a cardioprotective effect, which was abolished by 5hydroxydeconate (5HD), an inhibitor of the mitoKATP channel [44]. These findings have
been reported in several other studies of ischemia/reperfusion injury in animal models
where post-ischemic functional recovery significantly improved and infarct size was
reduced [42].
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Because of the key role of mitochondrial bioenergetics in cellular respiration and in
mitigating apoptosis, it is a promising target for potential development of novel therapeutic
applications in cardioprotection.

Intermediate filaments and Mitochondrial Permeability Transition Pore (MPTP)
Formation
Intermediate filaments play an integral role in cellular structure and function. Desmin, an
intermediate filament found in cardiomyocytes is localized to the Z-line where it supports
cellular integrity and stabilization of actin filaments [Figure 6A]. Moreover, desmin
integrates physical contraction of the myofibril via its linkage to adjacent myofibrils. In
addition to attachment to the Z-line, desmin also tethers the myofibrils to the sarcolemma,
nuclei, and to the mitochondria [Figure 6B]. In fact, desmin attaches to the mitochondrial
membrane contact sites, the same location where the VDAC and mitochondrial
permeability transition pore (MPTP) are formed [45]. Furthermore, desmin plays a vital
role in protecting the structural integrity of the myofibrils during mechanical stress. It is
conceivable that disruption of desmin either through repeated strain on the contractile
apparatus resulting from impaired contractility or through direct cleavage from activated
caspases may contribute to MPTP formation, cytochrome-c release, and apoptosis [Figure
6]. [45-51]

Although it is known that cardiomyocyte apoptosis contributes to dilated cardiomyopathy
and heart failure, there is increasing evidence that intermediate filaments such as desmin
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are involved in this pathological process [45]. Recently, Dinsdale et al [46] demonstrated
caspase-cleavage of intermediate filaments during apoptosis, which subsequently formed
intracytoplasmic aggregates. Moreover, a study using a transgenic mouse model (desmin /-) of desmin-related cardiomyopathy (DRM) demonstrated the ability of Bcl-2
overexpression in preventing DRM as evidenced by prevention of cardiomyocyte
apoptosis and preservation of cardiac contractility [45]. In addition, Wang et al [47]
demonstrated the disruption of desmin and formation of intracytoplasmic aggregates in a
mouse model of desmin-related cardiomyopathy. Furthermore, Heling et al [48] illustrated
the disorganization and accumulation of desmin in explanted human heart specimens from
patients with dilated cardiomyopathy.

Morphological changes including disruption of normal desmin distribution in myocytes as
observed in DRM are similar to those seen in other forms of cardiomyopathy and heart
failure [49]. Because intermediate filaments participate in the transmission of active force
[50], it is plausible that disruption of the filamentous network involving desmin may
significantly impair contractile force and result in sarcomere fragility.
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Figure 6A. Main Intermediate Filaments and Cytoskeletal Proteins Linking the Extracellular Matrix with
the Structural Muscle Proteins Associated with Mutations Causing Cardiac and Skeletal Myopathy.
& 2000 Massachusetts Medical Society, Dalakas, MC et al. N Engl J Med 2000; 342: p778.
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Figure 6B. Role of desmin in myofibrillar integrity. The mechanism of caspase-3
cleavage of desmin is depicted. Caspase-3 cleavage of desmin results in disruption of
normal contractile function and propagation of apoptosis via its interaction with the
mitochondria at the site of the MPTP (mitochondrial contact sites).
# 2005 Patrick W. Fisher, DO, PhD

.

MECHANISMS FOR PREVENTION OF DOXORUBICIN-INDUCED
CARDIOTOXICITY
Free Radical Scavengers & Iron Chelators
Most studies focusing on the development of pharmaceuticals aimed at preventing
doxorubicin cardiotoxicity have targeted mechanisms involved in production of free
radicals. Despite some success in pre-clinical experiments, many of these agents have
significant clinical disadvantages. For example, probucol, a lipid-lowering antioxidant,
confers significant protection against doxorubicin-induced cardiotoxicity [56]. However,
concerns about its high-density lipoprotein lowering properties and its potential to cause
QT-interval prolongation discourage its application in cancer patients [57]. The
cytoprotective drug amifostine is less potent than dexrazoxane (Zinecard), an iron chelator,
and it does not prevent the mortality and weight loss caused by doxorubicin in
spontaneously hypertensive rats [57,58]. In fact, it has also been shown to have some
benefit on prevention of acute doxorubicin cardiotoxicity but not on chronic cardiotoxicity
[59]. Finally, dexrazoxane, the only cardioprotective drug currently available clinically,
only reduces 50% of doxorubicin-related cardiac complications [60]. Moreover, it
interferes with the antitumor activity of anthracycline antibiotics and potentiates the
hematotoxicity of doxorubicin [60].
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Other potential pharmacological agents are free radical scavengers such as melatonin and
5-hydroxymethylrutoside. However, these agents have limitations in respect to dose and
frequency and concentration. Furthermore, clinical investigations are necessary to prove
their efficacy and safety in humans. [52,58]

Type-5A Phosphodiesterase Inhibition
Type-5 phosphodiesterase enzyme inhibitors are a class of drugs currently used clinically
to treat erectile dysfunction and pulmonary hypertension [71]. Because of the mechanism
of action, these agents show promise for potential targeting of cellular mechanisms that
promote doxorubicin-generated free radicals.
Phosphodiesterase enzymes convert the intracellular second messengers cyclic AMP and
cyclic GMP to the corresponding nucleotides AMP and GMP. There are now 11
phosphodiesterase families, many of which exist as splice variants. The cAMP-specific
enzymes include phosphodiesterase 4 (PDE4), -7 and -8. The cGMP-specific PDE’s are
PDE5, -6 and -9, whereas PDE1, -2, -3, -10 and -11 use both cyclic nucleotides [35]. Most
known PDE5 inhibitors compete with the substrate cGMP for binding to the protein at the
catalytic site. Although cGMP binding to the catalytic site stimulates cyclic-nucleotide
binding to the allosteric sites, inhibitors do not elicit the same property, and Ser92
phosphorylation has no effect on inhibitor binding. PDE5 is the primary cGMPhydrolyzing activity in human corpus cavernosum tissue. [60]
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Vasodilatory Effects of cGMP
Intense research in vascular smooth muscle physiology beginning more than two decades
ago lead to the discovery of sildenafil citrate, the first synthetic PDE-5 inhibitor for the
treatment of erectile dysfunction in men. Initial clinical studies using sildenafil focused on
its efficacy in treating systemic hypertension and coronary angina. The hypothesis behind
these early investigations stemmed from the theory that elevating cGMP levels via PDE-5
inhibition would result in systemic arterial vasodilatation. Although the results from early
studies using sildenafil for the treatment of coronary angina were disappointing, the sideeffect of penile erection, reported by many patients enrolled in this trial, inspired an
exciting new area of research leading to advancement in the treatment of patients with
erectile dysfunction [61,62].

Erection or tumescence is a neurovascular reflex mediated by smooth muscle
relaxation/contraction in cavernosal tissue [63]. Cavernosal smooth muscle cells are
normally in a “contracted state”, mediated via $-adrenergic neural stimuli with subsequent
phosphorylation of Ca+2/calmodulin-dependent myosin light chain kinase. In contrast,
tumescence is stimulated by parasympathetic CNS output via neural release of
acetylcholine. Consequently, NO is released from non-adrenergic, non-cholinergic
cavernosal nerves subsequently activating soluble guanylyl cyclase, the enzyme that
converts GTP to cGMP. The cyclic nucleotide then stimulates protein kinase G (PKG),
which initiates a protein phosphorylation cascade. This results in a decrease in
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intracellular levels of calcium ions, leading ultimately to dilation of the arteries that bring
blood to the penis and compression of the spongy corpus-cavernosum. This compression
contracts veins, reduces outflow of blood, and increases intracavernosal pressure,
ultimately resulting in tumescence. A PDE-5 inhibitor will retard enzymatic hydrolysis of
cGMP to 5’GMP in the human corpus cavernosum, leading to the same outcome. [63]

Role of Nitric Oxide (NO)
Nitric Oxide is well recognized as a key mediator in cell signaling processes. It is
produced from L-arginine through chemical reaction catalyzed by at least four major
isoforms of NOS, i.e. neuronal (nNOS), inducible (iNOS), endothelial (eNOS), and
mitochondrial NOS (mtNOS). In cellular studies, treatment with doxorubicin at 5 #M for
24 h increased the amount of iNOS protein without affecting either eNOS or nNOS
expression in H9C2 rat cardiac cells [105] The reduction in cardiac contractility in animals
given doxorubicin at 20 mg/kg i.p., was associated with a 3-4 fold increase in the
immunopositivity of myocardial iNOS (33±18 vs. 9±2%) and 3-nitrotyrosine formation
(56±24 vs. 0.3±0.4%) compared with the control group [106]. Pacher et al [107] reported a
decrease in ejection fraction and cardiac output which coincided with the increase in
cardiac nitrotyrosine synthesis in mice 5 days after the administration of doxorubicin at 25
mg/kg (IP). In these studies, iNOS (–/–) mice treated with doxorubicin displayed improved
cardiac function versus iNOS (+/+) litters. These findings suggest that the production of
peroxynitrite (ONOO-) by anthracyclines via iNOS was the critical mechanism of drug-
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induced cell injury in myocytes. In addition, it is suggested that elevated eNOS expression
and subsequent NO synthesis in bovine aortic endothelial cells was a result of doxorubicininduced hydrogen peroxide production.

Pharmacology of Sildenafil
Sildenafil citrate (Viagra ®) is an orally administered drug used for the treatment of
erectile dysfunction in men. It is a potent type-5 phosphodiesterase inhibitor, which blocks
the breakdown of cGMP. In humans, sexual arousal or stimulation results in release of NO
from penile vascular tissue increasing cGMP production with a subsequent cascade of
events resulting in: (1) vascular smooth muscle relaxation in the corpus cavernosa, (2)
engorgement of the lacunae, (3) compression of veins involved in draining blood from
cavernosal tissue, and ultimately (4) penile rigidity. [63]
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Pharmacokinetics of Sildenafil
After oral administration, sildenafil reaches peak plasma concentration within
approximately sixty minutes. Oral administration results in a bioavailability of
approximately 40% with 96% protein-bound. The half-life of sildenafil ranges between
three to five hours with clinical effects lasting 12 hours on average.
Sildenafil is metabolized by the liver and primarily excreted in the feces with a small
amount excreted in urine. The primary hepatic metabolism occurs by microsomal P450
enzymes (isoenzyme 3A4 and to a lesser extent, 2CA). Dose adjustment is warranted in
patients with hepatic disease, or who take any potent inhibitors of the P450 3A4 isoenzyme
including: (1) ketoconazole, (2) cimetidine, or (3) erythromycin to name a few.
Furthermore, because sildenafil is protein bound, caution should be used in patients taking
medicine that is also highly protein bound such as digoxin, amiodarone, or warfarin.
According to Shabsigh [61], the side-effect profile of sildenafil in patients with hepatic
impairment or who currently take inhibitors of P450 3A4 isoenzymes did not differ from
the general population despite significantly elevated plasma concentrations.

In addition to studies in humans, sildenafil has been shown to enhance nitric oxide (NO)driven cGMP accumulation in the corpus cavernosum of rabbits without affecting cAMP
formation. In the absence of NO drive, sildenafil had no functional effect on rabbit isolated
corpus cavernosum but potentiated the relaxant effects of NO on these tissues.
Furthermore, it has been shown that sildenafil causes mild to moderate decreases in
systolic and diastolic pressure because of the inhibition of PDE-5 in smooth muscle cells in
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the vascular bed. Prior studies in our laboratory confirmed the mild effect of sildenafil on
systemic hemodynamics in rabbits. [64]

SPECIFIC AIMS
In the present study, a series of novel investigations designed to examine the effect of
PDE-5 inhibitors in preventing doxorubicin-induced cardiotoxicity in mice was proposed.
Preliminary studies conducted in our laboratory by Fisher et al suggest the viability of our
major hypothesis that PDE-5 inhibitors may confer significant protection against
doxorubicin-induced cardiomyopathy, when administered in a prophylactic manner. The
purpose of this application is to show the effect of sildenafil on doxorubicin-induced
cardiomyocyte apoptosis and to attain a better understanding of the potential signaling
pathways in the heart that lead to cardioprotection in a chronic model of doxorubicininduced cardiotoxicity.

Accordingly, the main goals of the present study were:

1. To determine whether suppression of PDE-5 with the novel inhibitor, sildenafil,
attenuates doxorubicin-induced cardiotoxicity and contractile dysfunction via inhibition
of cardiomyocyte apoptosis in the heart. The effect of clinically relevant doses of
sildenafil on doxorubicin-induced cardiomyocyte apoptosis both in vivo and in vitro,
myocardial contractile dysfunction, and of Bcl-2 protein expression was investigated. It
was further that PDE-5 inhibition would inhibit doxorubicin-induced apoptosis via opening
of mitochondrial KATP channels; thereby preventing the collapse of mitochondrial
membrane potential (""m) and preventing opening of the mitochondrial permeability
transition pore (MPTP).
29
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2. To investigate if PDE-5 suppression will prevent myofibrillar disarray commonly
associated with cardiomyopathies. More specifically, the effect of prophylactic treatment
with sildenafil, at clinically relevant doses, on doxorubicin-induced disruption of desmin in
cardiomyocytes was examined. Moreover, it was proposed that PDE-5 inhibition would
attenuate the disruption of the normal desmin network in the heart, which is vital in
maintenance of myofibrillar integrity and myocardial contractility. Sildenafil-induced
opening of mitochondrial KATP channels, preservation of the mitochondrial membrane
potential, prevention of the MPTP formation, and subsequent caspase-3 activation
followed by DNA damage consistent with apoptosis will demonstrate this. The initial
hypothesis suggested that the latter would be prevented by increased Bcl-2 protein
expression ultimately inhibiting the translocation of Bax/Bad to the mitochondrial contact
site where the MPTP is located.

3. To evaluate the effect of PDE-5 inhibition in preventing chronic doxorubicin-induced
cardiotoxicity without affecting doxorubicin’s antineoplastic activity. To test this
hypothesis, the viability of PC-3 prostate cancer cells in vitro after treatment with
sildenafil plus doxorubicin, sildenafil alone, and with doxorubicin alone was studied. The
initial hypothesis was that the efficacy of doxorubicin in killing PC-3 cells, at a clinically
relevant dose (1uM), will not adversely affect prophylactic treatment with sildenafil.
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The aforementioned studies are the first to demonstrate the protective effect of PDE-5
inhibition in doxorubicin-induced cardiotoxicity in the heart at both the cellular and subcellular level. Moreover, this is the first study to demonstrate the prevention of
doxorubicin-induced cardiomyopathy coupled with the inability of sildenafil, at clinically
relevant doses, in adversely affecting the antineoplastic activity of doxorubicin.
Additionally, these studies provide relevant data setting the foundation for clinical trials
in humans receiving doxorubicin chemotherapy for hematological and/or oncological neoplasms.
Furthermore, these studies provide novel insights into expanding the utility of PDE-5
inhibitors their current use in the treatment of erectile dysfunction (ED) in men.

METHODS (In Vivo Model)
All animal studies were performed in accordance with the guidelines of the National
Institutes of Health (NIH) “Guide for the Care and Use of Laboratory Animals”, the
American Physiological Society and the Virginia Commonwealth University.
Adult male ICR mice (~33 grams each) were randomized to one of four groups. Group 1
saline only and served as a control. Group 2 received sildenafil (0.7 mg/kg i.p.) one hour
prior to the administration of an equivolume of saline in place of doxorubicin. Group 3
received an equivolume of saline one hour prior to doxorubicin (5 mg/kg i.p.). Group 4
received sildenafil (0.7 mg/kg i.p.) one hour prior to administration of doxorubicin (5
mg/kg i.p, Sigma Chemicals, St. Louis, MO). Animals were housed in a 12:12 hour
light/dark cycle, temperature-controlled room. Diet consisted of normal mouse chow
(Harlan, Indianapolis, IN) and water ad libitum.
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Figure 7. Experimental protocol. Treatment was administered on days 0, 7, and 14.
Groups II and IV were administered sildenafil 1 hour before either saline or doxorubicin,
respectively. Group III received saline 1 hour before doxorubicin. ECG (lead II) was
performed 2 days after each treatment and 1 week thereafter for 8 weeks. LV indicates left
ventricular.
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Cardiomyocyte Apoptosis
Cardiomyocyte apoptosis was evaluated via the terminal dUTP nick-end labeling method
(TUNEL) using the ApopTag® In Situ Apoptosis Detection Kit (Chemicon, Temecula,
CA) according to the manufacturer’s instructions. The quantification of apoptosis or
Apoptotic Index (AI) was determined by counting TUNEL (+) myocyte nuclei from ten
random fields per section and expressed as a percentage of total myocyte nuclei. Because
the TUNEL assay can detect DNA damage from non-apoptotic stimuli, complementary
analysis was conducted using the ApopTag® In Situ Oligo Ligation (ISOL) technique
(Chemicon, Temecula, CA). The ISOL method uses T4 DNA ligase to specifically ligate
DNAase Type I ends to biotin-labeled hairpin oligonucleotides. The localization of
oligonucleotides (labeled) is restricted to regions of chromatin characteristic for apoptosis.
The ISOL method does not label nicks, gaps, or ssDNA, 3’recessed ends or 3’overhanging
ends longer than one dT base. These techniques have been used together for appropriate
labeling of DNA characteristic of apoptosis [56,74-75].

35
Desmin Immunofluorescence

Distribution of desmin, an intermediate filament important in cellular integrity and
myocyte contraction, was analyzed in frozen sections (5 #m) in animals from each of the
experimental groups. After appropriate fixation in 4% paraformaldehyde, samples were
incubated for one hour with 10% normal goat serum. Next, primary goat anti-desmin
antibody (Santa Cruz Biotech, Santa Cruz, CA), diluted 1:50 was applied to each slide and
incubated for one hour at room temperature. After several washes, Alexa Fluor 488
donkey anti-goat secondary antibody (Molecular Probes, Eugene, OR), diluted 1:400 was
applied to each slide. Samples were incubated for one hour at room temperature. After
several washes in 1X PBS, Prolong Gold® Antifade (Molecular Probes, Eugene, OR) was
applied followed by mounting with a glass coverslip. Visualization of desmin distribution
was accomplished using a Nikon epifluorescent microscope with a 60X oil objective and a
FITC filter cube. Image acquisition was obtained using MicroPublisher® 3.3 CCD camera
with Q-Capture® Professional image analysis software (QImaging, Burnaby, B.C.
Canada).
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Analysis of BCL-2 Expression
Mice whole heart proteins were extracted with RIPA buffer (Upstate™, Charlottesville,
VA) and proteins were separated on SDS-PAGE and transferred onto 12% nitrocellulose
membranes (Bio-Rad, Hercules, CA). Primary antibodies against Bcl-2 (Molecular weight:
28kDa) were followed by secondary rabbit IgG-conjugated horseradish peroxidase
antibody according to manufacturer’s instructions (Santa Cruz Biotech, Santa Cruz, CA).
Antibodies against '-actin (Molecular weight: 39 kDa) were used for determination of
protein loading (Santa Cruz Biotech, Santa Cruz, CA). Densitometry was performed using
BioQuant® software (BioQuant, Nashville, TN).

Hemodynamics
Animals (n = 6/group) were sacrificed at 2,4 and 8 weeks after the last day of treatment
(day 14). After adequate anesthetization using pentobarbital (100 mg/kg i.p), the heart was
excised and immediately placed in cold saline (4°C). The heart was then cannulated via
the aorta and retrogradely perfused at a constant perfusion pressure equivalent to 100
cmH2O. All hearts were perfused with modified Krebs-Henseleit (K-H) buffer at 37°C,
containing (in mM) 118.5 NaCl, 25.0 NaHCO3, 3.2 KCl, 1.19 MgSO4, 1.25 CaCl2, 1.2
KH2PO4, and 11 glucose and was bubbled with 95% O2-5% CO2 mixture. The pH was
maintained at 7.4. After the heart began spontaneous contraction, a small incision was
made in the left atrium. A latex balloon connected to a pressure transducer via
polyethylene cannula was inserted through the left atrium and mitral valve into the left
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ventricle. The balloon was filled with enough water to increase end-diastolic pressure
(EDP) to approximately 10 mmHg. Left ventricular systolic pressure (LVSP), left
ventricular developed pressure (LVDP), and heart rate (HR) were recorded (Chart 4.0, AD
Instruments, Colorado Springs, CO). LVDP was calculated by subtracting EDP from the
LVSP. Rate pressure product (RPP), an index of myocardial oxygen demand and
workload, was calculated by multiplying LVDP with HR. Coronary flow reserve was
measured by timed collection of coronary effluent. Care was taken to maintain
temperature of the heart at 37°C.

Electrocardiography
A separate set of four groups (n=6/group) was utilized for the assessment of
electrocardiographic (ECG) changes indicative of doxorubicin cardiotoxicity [76,77].
More specifically, this technique will further confirm the presence of doxorubicin-induced
cardiotoxicity throughout the course of the investigation (10 weeks) as initially proposed
by Fisher. All animals were weighed at baseline and every 7-10 days for 8 weeks prior to
the ECG analysis. Animals were anesthetized using pentobarbital (50 mg/kg IP) followed
by insertion of electrodes in the left front limb, right front limb, left hind limb, and right
hind limb. The electrodes were connected to an electrocardiography module (LDS Life
Science, Valley View, CA) and data was recorded for 2-3 minutes per animal. The STinterval was measured in five consecutive complexes using Ponemah® physiology
software (LDS Life Science, Valley View, CA). ST-interval duration was measured at
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baseline, 48-72 hours after each dose of doxorubicin (Days 0, 7, and 14 ± 2-3 days) and
every 7-10 days thereafter until 8-weeks was attained.

METHODS (In Vitro Model)

Isolation of Adult Cardiomyocytes

Adult male outbred ICR mice (Harlan, Indianapolis, IN) were used in isolation of
ventricular myocytes. Ventricular myocytes were isolated using an enzymatic technique.
Briefly, mice (n = 3/experiment) were anesthetized with pentobarbital (100 mg/kg IP) and
the heart was quickly removed from the chest. Within 3 minutes, the aortic opening was
cannulated and placed onto a Langendorff perfusion system. Next, the heart was
retrogradely perfused (37°C) at a constant pressure of 55 mmHg for 5 minutes with a Ca+2
-free bicarbonate-based buffer containing (in mM): 120 NaCl, 20 NaHCO3, 5.4 KCl, 1.2
MgSO4, 1.2 NaH2PO4, 5.6 glucose, 10 2,3-butanedione monoxime, and 5 taurine, which
was gassed with 95% O2-5% CO2 mixture. The enzymatic digestion was commenced by
adding collagenase type II (Worthington, 0.5 mg/ml each) and protease type XIV (0.02
mg/ml) to the perfusion buffer and continued for ~15 minutes. Following initial enzymatic
digestion, 50 #M Ca+2 was added to the enzyme solution and the heart was perfused for
an additional 10-15 minutes. Digested ventricular tissue was cut into chunks and gently
aspirated with a transfer pipette for facilitating cell dissociation. The cell pellet was
resuspended for a 3-step Ca+2 restoration procedure (i.e. 125, 250, 500 #M Ca+2).
Freshly isolated cardiomyocytes were suspended in minimal essential medium (Sigma,
Catalogue # M1018, pH 7.35-7.45) containing 1.2 mM Ca+2, 12 mM NaHCO3, 2.5% fetal
bovine serum, and 1% penicillin-streptomycin. Cells were plated onto 2-chamber slides,
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which were pre-coated with 20 #g/ml mouse laminin in PBS + 1% penicillin-streptomycin
for 1 hour. Cardiomyocytes were cultured in the presence of 5% CO2 for 1 hour in a
humidified incubator at 37°C. Myocyte cultures were randomly assigned to one of 12
treatments: (1) control; (2) sildenafil (1 #M); (3) doxorubicin (1 #M); (4) sildenafil (1#M)
one hour prior to doxorubicin (1#M); (5) 5-Hydroxydecanoate (5-HD), a mitoKATP
channel blocker (100 #M); (6) 5-HD (100 #M) one hour prior to doxorubicin (1 #M); (7)
5-HD (100 #M)+ sildenafil (1 #M); (8) 5-HD (100 #M)+sildenafil (1 #M) one hour prior
to doxorubicin (1 #M); (9) NG-nitro-L-arginine methyl ester (L-NAME), a nitric oxide
synthase (NOS) inhibitor (100 #M); (10) L-NAME (100 #M) one hour prior to
doxorubicin (1 #M); (11) L-NAME (100 #M)+ sildenafil ( 1 #M); or (12) L-NAME (100
#M)+ sildenafil (1 #M) one hour prior to doxorubicin (1#M). Slides were incubated for
18 hours followed by several washes in 1X PBS prior to analysis.

Cardiomyocyte Apoptosis (In Vitro)
Cardiomyocyte apoptosis was evaluated via the terminal dUTP nick-end labeling method
(TUNEL) using the ApoAlert™ DNA Fragmentation Assay Kit (BD Biosciences, Palo
Alto, CA) according to manufacturer’s instructions. Equilibration buffer was used in place
of working TdT reagent for use as a negative control. DNAase-I was applied and used as a
positive control. Analysis was performed using a Nikon epifluorescent microscope with
20x objective. A FITC filter cube was utilized in detection of apoptotic myocyte nuclei.
An ultraviolet filter cube was utilized in detection of DAPI-stained myocyte nuclei.
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Apoptotic index (AI) was determined from counting TUNEL-positive myocyte nuclei from
ten separate fields per treatment and expressed as a percentage.
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Active Caspase-3 Detection
Active Caspase-3 staining was determined using the CaspaTag™ In Situ Assay Kit
(Chemicon, Temecula, CA) according to manufacturer’s instructions. This assay is based
on Fluorochrome Inhibitors of Caspases (FLICA). The inhibitor binds covalently to the
active caspase. This kit uses a carboxyfluorescein-labeled fluoromethyl ketone peptide
inhibitor of caspases-3 and -7 (SR-DEVD-FMK), which emits a red fluorescence. The SRDEVD-FMK probe enters each cell and covalently binds to reactive cysteine residue on the
large subunit of the active caspase heterodimer, thereby inhibiting enzymatic activity. The
bound labeled reagent is retained within the cell. The red fluorescent signal is a direct
measure of active caspase-3 in the cell at the time the reagent was added. After application
of CaspaTag™ reagent and Hoechst, cells were immediately examined using a Nikon
epifluorescent microscope with rhodamine (Active Caspase-3) and ultraviolet (Hoechst)
bandpass filters.
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Assessment of Mitochondrial Membrane Potential (!"m)
Loss of ""m was assessed using epifluorescent microscopy. Cultured adult mouse
ventricular myocytes were stained with 5,5’, 6,6’-tetrachloro-1, 1’, 3,3’tetraethylbenzimidazole-carbocyanide iodine (JC-1, Biocarta, San Diego, CA) after an 18
hour incubation. Cells were incubated with 2 #g/ml JC-1 for 10 minutes at 37ºC. After
washing with 1xPBS, cells on chamber slides were scanned with a Nikon epifluorescent
microscope using a 20x objective lens. Fluorescence was analyzed using a Texas RedFITC filter cube. Red emission of the dye represented a potential-dependent aggregation
in the mitochondria, reflecting ""m. Green fluorescence represented the monomeric form
of JC-1, appearing in the cytosol after mitochondrial membrane depolarization. The ratio
of mitochondrial aggregates (red) to the monomeric form of JC-1 (green) was analyzed
using Q-Capture® Professional image analysis software (QImaging, Burnaby, B.C.
Canada). Myocytes were counted from ten separate fields per group and expressed as a
ratio of mitochondrial aggregates to the monomeric form of JC-1.

44
Cell Viability Assay
In order to determine if sildenafil affects the antitumor efficacy of doxorubicin, a highly
effective and accurate technique, using PC-3 prostate cancer cell line was utilized. PC-3
prostate cancer cells (American Cell Culture, Manassas, VA), which are p53-deficient and
susceptible to doxorubicin, were cultured in F12-K medium supplemented with 10% fetal
bovine serum. Approximately 4,000 PC-3 cells/well were plated into one-half of a 96-well
dish while the other half of the 96-well dish was incubated with 8,000 PC-3 cells/well and
allowed to attach overnight. Lane 1 consisted of PC-3 cells plus culture media alone. Lane
2 was treated with doxorubicin (80 nM). Lane 3 was treated with doxorubicin (1 uM).
Lane 4 was treated with sildenafil (1 uM) one-hour before doxorubicin (80 nM). Lane 5
was treated with sildenafil (1 uM) one-hour before doxorubicin (1 uM). Lane 6 was
treated with sildenafil (1 uM). Lane 7 was treated with sildenafil (10 uM). Wells 1-3 & 79 of Lane 8 were treated with sildenafil (10 uM) one-hour before doxorubicin (1 uM).
Wells 4-6 & 10-12 of Lane 8 were treated with PC-3 cells in culture media only. Cell
viability or the number of surviving cells was measured 4 days after doxorubicin
application with CellTiter-Blue( Cell Viability Assay according to manufacturer
instructions (Promega). CellTiter-Blue( reagent (20ul/well) was added and incubated for
one-hour before recording absorbance at 570nm and 600 nm using a VersaMax microplate
reader with SoftMaxPro software (Molecular Devices). The average absorbance (600nm)
values of the culture medium background was subtracted from all 570nm values of
experimental wells. Next, the 570-600nm absorbance versus concentration of test
compound was analyzed. The CellTiter-Blue( Cell Viability Assay uses the indicator dye,
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resazurin, to measure the metabolic activity of cells as an indicator of cell viability. Viable
cells, for example, are capable of reducing resazurin to the highly fluorescent resafurin.
Because non-viable cells cannot reduce resazurin to resafurin, the fluorescence or
absorbance is negligible. The absorbance obtained from this assay is proportional to the
number of viable cells.

Flow Cytometry
To confirm our results demonstrating the inability of sildenafil in affecting the antitumor
efficacy of doxorubicin in vitro using PC-3 cancer cells, we subsequently measured cell
viability using flow cytometry (Beckman Coulter Flow Cytometer; 488nm laser).
Calibration for doxorubicin autofluorescence and propidium iodide was conducted before
analysis. The experimental groups included: control, doxorubicin (1, 2 and 5 µM),
sildenafil (1 and 2 µM), doxorubicin (1 #M)+ sildenafil (1 or 10 #M), doxorubicin (2
#M)+sildenafil (1 or 10 #M), and doxorubicin (5 #M)+sildenafil (10 #M). In this
approach, instead of using a compound that is actively reduced by viable cells (resazurin),
we utilized the impermeable nucleic acid dye, propidium iodide (Sigma-Aldrich), to detect
the amount of non-viable cells. Since non-viable cells would have disruption of their
nuclear membrane, it is expected that necrotic cells would actively stain with propidium
iodide and be detected using flow cytometry. Controls containing doxorubicin only,
doxorubicin + propidium iodide, propidium iodide + media, and media only were added as
additional controls. Flow cytometric data are depicted in Appendix E.
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Statistics

Data are presented as mean ± SEM. Difference between groups was analyzed with
unpaired t test or one-way ANOVA followed by Tukey-Kramer HSD post-hoc test (JMP,
Version 5, SAS Institute Inc., Cary, NC). P<0.05 was considered as statistically significant.

RESULTS (In Vivo)
Cardiomyocyte apoptosis
Prior studies have implicated cardiomyocyte apoptosis in the development of chronic
cardiomyopathy induced by doxorubicin administration [75,76]. The following results
indicate the powerful cardioprotection of sildenafil via mitigation of cardiomyocyte
apoptosis in the experimental group receiving sildenafil. Data from both TUNEL and
ISOL techniques demonstrated significant cardiomyocyte apoptosis in doxorubicin group
compared to saline control at 2, 4, 6, and 8-weeks post-treatment (P<0.001). Sildenafil
attenuated doxorubicin -induced cardiomyocyte apoptosis when administered one hour
before each of three separate treatments with doxorubicin (5 mg/kg IP; 15 mg/kg total
cumulative dose). These results were similar to saline control animals [Figure 8 A-D].
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Figure 8A. Apoptotic Index using both TUNEL and ISOL techniques in experimental
groups at (A) 4 and (B) 6 weeks post treatment.
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Figure 8B. Apoptotic Index using both TUNEL and ISOL techniques in experimental
groups at (C) 8 and (D) 10 weeks.
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Bcl-2 expression
The Bcl-2 family of proteins provides maintenance of the integrity of the outer
mitochondrial membrane [78]. Pro-apoptotic Bcl-2 family of proteins including Bax, Bak,
and t-Bid can integrate into the outer mitochondrial membrane in response to apoptotic
stimuli inducing cytochrome-c release via mitochondrial transition permeability pore
(MPTP) formation [79, Figure 10]. However, binding of Bcl-2 or Bcl-XL inhibits
membrane integration of pro-apoptotic Bcl-2 family of proteins and subsequent MPTP
formation. [80, 81]. In the present study, a significant decrease in Bcl-2 expression was
observed at 2-weeks and 8-weeks post treatment in the doxorubicin group compared to
both sildenafil + doxorubicin and control group. Moreover, Bcl-2 expression was
maintained when sildenafil was given one hour before doxorubicin treatment [Figure 9].
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Figure 9. Western Blot of Bcl-2 Protein at 2 Weeks after Treatment (week 4), (A) and 8
weeks after treatment (week 10) (B). Bar Graph represents densitometric quantification
from 3 individual hearts per group, which is normalized against the actin level for each
sample. Data are Mean±SEM. Abbreviations are defined in Figure 7 legend.
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Figure 10. Illustration demonstrating the effect of PDE-5A inhibition on mitochondrial
bioenergetics in the presence of doxorubicin. & 2005 Patrick W. Fisher DO, PhD.
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Doxorubicin-induced myofibrillar disarray (desmin distribution)
At 8-weeks post treatment, doxorubicin group exhibited myofibrillar disarray as evidenced
by abnormal desmin distribution, lack of Z-line integrity, and abnormal cytoplasmic
desmin aggregation. In contrast, sildenafil+doxorubicin group displayed normal desmin
distribution as evidenced by immunofluorescent staining throughout the entire cytoplasm
with clear delineation of Z-lines. This was similar to both control and sildenafil +saline
groups. [Figure 11]
Furthermore, PDE-5A expression was significantly reduced in the doxorubicin-only group
at 8 weeks post treatment. This reduced expression and lack of localization to the z-line
was most marked in the area of the cardiomyocyte where desmin disruption was evident
[Appendix B, C].
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Figure 11. Immunofluorescent staining for desmin (green) in cryo-sections from mice in
the saline control (A), sildenafil (B), sildenafil+doxorubicin (C), and doxorubicin (D & E)
groups at 8 weeks after treatment. In control, sildenafil, and sildenafil+doxorubicin groups
(A, B, C), desmin staining is present throughout the entire cytoplasm and is observed at the
Z-lines demonstrated as green striations (arrowheads). In the doxorubicin-treated group
(D, E), obvious disruption of the desmin network is present, with loss of Z-line
localization. Areas of decreased uptake of anti-desmin antibody are apparent (star).
Nucleus (N). Magnification X600; E, image acquired with a Zeiss LSM 510 Confocal
Microscope (Figure E: & 2005 Patrick W. Fisher, DO, Phd)
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Electrocardiography (ECG)
Prior studies in mice demonstrated a strong correlation between ST-interval duration and
doxorubicin-induced cardiotoxicity [76,77]. In contrast to ECG recordings in humans, the
ECG (Lead II) in mice does not contain an ST-segment. The T-wave immediately follows
the QRS complex [76,77]. Prolongation of the ST-interval in doxorubicin-treated mice is
secondary to an increase in action potential duration (APD) [77]. Le Marc et al [82]
observed an increase in APD in Purkinje fibers after incubation with doxorubicin.
Furthermore, in isolated cardiomyocytes exposed to doxorubicin, Jabr et al [83] observed
APD prolongation resulting from doxorubicin -generated ROS. In experimental groups
receiving doxorubicin, a significant progressive increase in ST-interval was observed at all
time points compared to baseline [Figure 12]. Moreover, the most marked increase in STinterval occurred between week 4 and week 8. Furthermore, ECG’s of the control and
sildenafil+ doxorubicin group did not change during the course of the study. Sildenafil
significantly protected against ST-interval prolongation throughout the study period.
[Figure 12]
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Figure 12. Electrocardiographical Analysis of ST-Prolongation in mice (lead II). Effect of
sildenafil on ST-interval prolongation after doxorubicin treatment. ST interval was
measured with the use of lead II. A, ST-interval prolongation over time. Representative
tracings of control (B), sildenafil+doxorubicin (C), and doxorubicin only (D) are shown.
Data are mean±SEM (n=6/group). Abbreviations are as defined in Figure 7 legend.
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Effect of sildenafil on cardiac function in doxorubicin-treated animals
Our data shows a significant decline in LVDP in the saline+ doxorubicin group compared
to control at 2 weeks post treatment (27% vs control; 24% vs sildenafil+ doxorubicin)
[Table 1]. Decline in contractility as measured by rate pressure product (RPP) persisted
through 8 weeks after treatment cessation in the saline+ doxorubicin group. Animals
treated prophylactically with sildenafil before doxorubicin demonstrated RPP that
remained unchanged from control over 8-week post-treatment period.
[Figure 13]

Figure 13. Bar graph representing rate pressure product in mouse hearts via Langendorff
mode at 4, 6, and 10-weeks post-treatment. Data are mean ± SEM (n = 6/group/time point).
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Table 1. Hemodynamic Indices
Week 2
HR

Group

(bpm)

LVDP

Week 4
RPP

HR
-1

(mmHg) (mmHg•min )

(bpm)

Control
SIL
DOX

LVDP

Week 8
RPP

HR
-1

(mmHg) (mmHg•min )

384±4 99±3 35116±1121
410±1
92±1
393±5 101±3 36905±1342* 399±11
106.6±3
439±11* 72±4* 28099±1562* 374±13* 68±4*
SIL+DOX 381±6** 95±3** 33471±1290** 381±11** 102±3

(bpm)

LVDP

RPP

(mmHg) (mmHg•min-1)

34851±1057
412±8
90±1 34159±651
39762±1588* 412±4†
93±1 35296±437*
22108±1248*† 365±15*† 62±3*† 19716±947*†
35861±1238** 409±2** 92±1 34827±413**

* P <0.05 vs. control, ** P <0.05 vs. DOX, † P <0.001 vs. Week 2.
Abbreviations: HR= heart rate; LVDP= left ventricular developed pressure; RPP= rate pressure product;
SIL= sildenafil+saline; SIL+DOX= sildenafil+doxorubicin; DOX= saline+doxorubicin

& 2005 Patrick W. Fisher, DO, PhD.

RESULTS (IN VITRO)

Cardiomyocyte Apoptosis
Treatment of cardiomyocytes with doxorubicin (1 #M) for 18 hours resulted in a
significant increase in TUNEL (+) nuclei as indicated by Apoptotic Index (AI) of 0.61 ±
0.09%, which was similar to both L-NAME+sildenafil+doxorubicin (0.62±0.08%) and 5HD+sildenafil+doxorubicin (0.60±0.10%) groups. In contrast, a significant inhibition of
apoptosis was evident in the sildenafil+doxorubicin (0.078±0.031%) group, which was
similar to control (0.078 ± 0.032%) [Figure 14]. Additionally, active caspase-3 expression
increased in the doxorubicin, sildenafil+L-NAME+ doxorubicin, and 5HD+sildenafil+
doxorubicin groups compared to sildenafil+ doxorubicin and control groups. [Figure 15]

Figure 14. Apoptotic Index of Adult Ventricular Myocytes (TUNEL).
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Figure 15A. Activated caspase-3 in adult mouse ventricular myocytes (red; left
column) with myocyte nuclei stained with Hoechst (blue; right column). A,
Control; B, doxorubicin; C, sildenafil plus doxorubicin; Magnification x200; n=3.
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Figure 15B. Activated Caspase-3 in Adult Ventricular Cardiomyocytes
D, sildenafil (1 µM); E, L-NAME (100 µM) plus sildenafil plus doxorubicin; F,
5-HD (100 µM) plus sildenafil (1 µM) plus doxorubicin. Magnification x200; n=3.
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Assessment of Mitochondrial Membrane Potential (!"m)
Exposure of adult mouse ventricular myocytes to doxorubicin (1 µM) for 18 hours resulted
in dissipation of !"m as illustrated via JC-1 immunofluorescent staining [Figure 16]. In
contrast, myocytes pretreated with sildenafil (1 µM) before treatment with doxorubicin
demonstrated preservation of the !"m. The latter result was similar to both control and
sildenafil+ doxorubicin groups [Figure 17]. However, dissipation of !"m occurred in
both the L-NAME (100 µM)+sildenafil+ doxorubicin and 5-HD (100 µM)+sildenafil+
doxorubicin groups. [Figure 16]
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Figure 16. Effect of Sildenafil on ""m in Adult Ventricular Cardiomyocytes. Red
Fluorescence represents the mitochondrial aggregate form of JC-1, indicating intact
mitochondrial membrane potential. Green Fluorescence represents the monomeric
form of JC-1, indicating dissipation of ""m. A, Control; B, sildenafil (1 #M); C,
doxorubicin (1 #M); D, sildenafil (1 #M) plus doxorubicin (1 #M); E, L-NAME (100
#M) plus sildenafil plus doxorubicin; F, 5-HD (100 #M) plus sildenafil plus
doxorubicin.
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Figure 17. Ratio of Mitochondrial Aggregates to the Monomeric Form of JC-1. Data are
expressed as Mean ± SEM.
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Effect of Sildenafil on the Antitumor Efficacy of Doxorubicin
Cell Viability Assay
Using absorbance as a measure of cell viability, the administration of doxorubicin at a
concentration of 80 nM did not significantly inhibit the growth of PC-3 cells in vitro. In
contrast, doxorubicin at a concentration of 1 uM significantly decreased the ability of PC3 cells to reduce resaruzin to the highly fluorescent resafurin. In other words,
doxorubicin at a concentration of 1 uM killed approximately 65% of PC-3 cells when
administered alone. Additionally, the administration of sildenafil at concentrations of
either 1 uM or 10 uM one-hour before the administration of doxorubicin, did not effect
the antitumor efficacy of doxorubicin in PC-3 cells in vitro. Moreover, when sildenafil (1
uM or 10 uM) was administered alone, the viability of PC-3 cells was not significantly
altered.
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Figure 18. Photograph of 96-well Microplate used in the Cell Viability Assay of
sildenafil on the antitumor efficacy of doxorubicin. Lane 1 & Lane 8 (Wells 4-6 &10-12),
Media only; Lane 2, DOX (80 nM); Lane 3, DOX (1 uM); Lane 4, sildenafil
(1uM)+DOX (80 nM); Lane 5, sildenafil (1 uM)+DOX (1 uM); Lane 6, sildenafil (1 uM),
Lane 7, sildenafil (10 uM); Lane 8 (Wells 1-3 & 7-9), sildenafil (10 uM)+DOX 1 uM).
© 2005 Patrick William Fisher, DO, PhD
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Figure 19. Cell Viability of PC-3 Prostate Cancer Cells (in vitro). The absorbance is
proportional to the number of viable cells. ! 2005 Patrick W. Fisher, DO, PhD.
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Figure 20. Flow cytometry data assessing the percentage of cell death in PC-3 prostate
cancer cells in vitro after treatment with varying concentrations of doxorubicin with or
without sildenafil, A. Cell death (% of PC-3 prostate cancer cells) versus doxorubicin
concentrations (1, 2, and 5 µM), B. Cell Death was determined using propidium iodide
(50 µg/ml). Subtraction of doxorubicin autofluorescence was performed prior to flow
cytometric analysis. Data are Mean +/- SEM. © 2005 Patrick William Fisher, DO, PhD

DISCUSSION
For the first time, it is demonstrated that treatment with clinically relevant doses of
sildenafil (0.7 mg/kg IP) one hour prior to doxorubicin resulted in cardioprotection from
doxorubicin-induced cardiotoxicity. More specifically, the aforementioned data illustrate
the capacity of sildenafil in attenuation of cardiomyocyte apoptosis, maintenance of the
!"m, preservation of myofibrillar integrity, prevention of left ventricular dysfunction, and
prevention of ST-prolongation consistent with chronic doxorubicin toxicity 8-weeks after
the final of three treatments.

The initial hypothesis behind pharmacological preconditioning with sildenafil was that the
vasodilatory action of sildenafil could potentially release endogenous mediators of
preconditioning such as adenosine or bradykinin from endothelial cells triggering
phosphorylation of nitric oxide synthase (NOS) and subsequent release of nitric oxide
(NO) [63]. The generation of NO could then serve to activate sGC with increased
formation of cyclic guanyl monophosphate (cGMP). Increase in cGMP is believed to be
responsible for activation of protein kinase G (PKG) and subsequent opening of mitoKATP
channels in acute and delayed cardioprotection [63]. Previously, it was demonstrated that
sildenafil-induced delayed preconditioning was linked to a NOS-dependent mechanism in
mice [64]. Moreover, both the acute and delayed cardioprotective effects of sildenafil in
an in vivo rabbit model were blocked by 5-HD, supporting the significance of mitoKATP
channel opening in sildenafil-induced cardioprotection.
69
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In addition to the present in vivo model of sildenafil-induced cardioprotection from
doxorubicin as developed by Fisher, an in vitro model of adult mouse ventricular myocytes
was utilized to further investigate the mechanism of protection by sildenafil. In this study,
prophylactic administration of sildenafil inhibited doxorubicin-induced !"m dissipation,
caspase-3 activation, and cardiomyocyte apoptosis. This protection was completely
abolished by both L-NAME and 5-HD. These findings infer that sildenafil-mediated
protection from doxorubicin-induced cardiomyocyte apoptosis is NOS-dependent and
establishes a significant role of mitoKATP channel opening in sildenafil-induced
cardioprotection.

The exact mechanism of NO/cGMP in protection from doxorubicin cardiotoxicity is not
fully explicable. It has been shown that doxorubicin-generated H2O2 induces a massive
increase in eNOS gene transcription followed by generation of extremely high levels of
NO favoring potentiation of ROS and reactive nitrogen species [84]. In contrast, exposure
to low nonlethal levels of endogenous NO induces adaptive responses by continuous
stimulation of sGC with maintenance of basal cGMP levels, rendering cells resistant to
lethal concentrations of NO or peroxides [85]. Moreover, it has been reported that
physiologically stimulated sGC by NO preserved !"m and inhibited apoptosis [86,87] and
caspase-3 activation [88]. From the current results, it is plausible that pretreatment with
sildenafil prior to an onslaught of doxorubicin-generated free radicals augments inherent
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cellular adaptive mechanisms mediated by endogenous NO/cGMP, leading to maintenance
of mitochondrial bioenergetics and inhibition of apoptosis.

Doxorubicin-induced cardiomyocyte apoptosis occurs via both the extrinsic and intrinsic
pathways [89,90]. However, using this model substantiates the significance of the intrinsic
pathway of apoptosis in both normal and pathophysiological processes. Prior studies have
identified the mitochondria as the main target of doxorubicin accumulation in cardiac cells
[91]. Mitochondrial NADH dehydrogenase contributes to doxorubicin-generated ROS
production via redox cycling of doxorubicin to its semiquinone [92]. Furthermore,
mitochondrial concentrations of doxorubicin (5-50 µM) are several folds greater than
simultaneous clinically relevant serum concentrations (0.1-1uM) [93]. Consequently, the
relatively limited supply of both catalase and glutathione peroxidase (GSH-Px) is rapidly
expended in the heart; thus creating an environment that promotes hydroxyl radical
production [94]. Accordingly, the accumulation of ROS results in dissipation of the !"m,
direct activation of the MPTP, and cytochrome-c release followed by caspase-3 activation
and DNA fragmentation consistent with apoptosis [95].

In the present study, a significant decline in Bcl-2 expression both at 2-weeks and 8-weeks
post treatment in the doxorubicin group compared to the sildenafil+doxorubicin group and
control was observed, suggesting an important role of Bcl-2 in altering the pathological
process leading to end-stage heart failure. Furthermore, significant differences in desmin
distribution between the doxorubicin group compared to all other groups was evident
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[FIGURE 11, Appendix B]. In the doxorubicin group, desmin distribution was clearly
disrupted with areas of decreased staining in the cytoplasm consistent with desmin
aggregation. In contrast, sildenafil+doxorubicin group displayed an intact desmin network
similar to control. Although it is known that cardiomyocyte apoptosis contributes to
dilated cardiomyopathy and heart failure, there is increasing evidence that intermediate
filaments such as desmin are involved in this pathological process [96]. Recently,
Dinsdale et al [97] demonstrated caspase-cleavage of intermediate filaments during
apoptosis. Moreover, a study using a transgenic mouse model (desmin -/-) of desminrelated cardiomyopathy (DRM) demonstrated the ability of Bcl-2 overexpression in
preventing DRM as evidenced by prevention of cardiomyocyte apoptosis and preservation
of cardiac contractility [96]. In addition, Wang et al [98] demonstrated the disruption of
desmin and formation of intracytoplasmic aggregates in a mouse model of DRM.
Furthermore, Heling et al [99] illustrated the disorganization and accumulation of desmin
in explanted human heart specimens from patients with dilated cardiomyopathy.
Consistent with findings by Heling [99] and Wang [98], we demonstrated disruption of
desmin in the doxorubicin group compared with the sildenafil+doxorubicin and control
groups. Moreover, morphological changes including disruption of normal desmin
distribution in myocytes as observed in DRM are similar to those seen in other forms of
cardiomyopathy and heart failure [100]. Because intermediate filaments participate in
transmission of active force [101], it is plausible that disruption of the filamentous network
involving desmin may significantly impair contractile force and result in sarcomere
fragility. Also, since desmin is known to adhere to the mitochondria in the same location
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where the MPTP is formed, it is conceivable that disruption of desmin either through
repeated strain on the contractile apparatus resulting from impaired contractility or through
direct cleavage from activated caspases may contribute to MPTP formation, cytochrome-c
release, and apoptosis.

In the current study, an 8-week post-treatment strategy was utilized, which is adequate in
demonstrating many of the pathological findings of chronic doxorubicin-induced
cardiotoxicity. Moreover, it provides an animal model that parallels the clinical
progression of this disease in humans. In addition, it serves as a unique and powerful
model to understand many of the common factors that are shared by most forms of clinical
cardiomyopathies.

Results from in vitro studies using PC-3 cancer cells testing the effect of sildenafil on the
efficacy of the antineoplastic action of doxorubicin provide relevant pre-clinical safety and
efficacy data that are required prior to eventual clinical trials in humans.

Because sildenafil has proven to be relatively safe and effective in treating both erectile
dysfunction and pulmonary hypertension [102,103], it is conceivable that sildenafil may
provide an additional tool to hematologists and oncologists in preventing cardiotoxicity.
Moreover, sildenafil prophylaxis during doxorubicin treatment may potentially allow an
increase in the dose of doxorubicin beyond the cumulative limitation of 450-600 mg/m2
[104], thereby expanding its therapeutic window. Studies using flow cytometry assessing

74
the cytotoxicity of doxorubicin on PC-3 cancer cells in vitro, demonstrate a powerful
synergistic effect when sildenafil is combined with doxorubicin. This in vitro effect of
sildenafil on the antineoplastic action of doxorubicin is presently being evaluated by Fisher
et al using an in vivo nude mouse model with subcutaneously injected human breast cancer
cells known to be susceptible to doxorubicin.

The powerful synergy between doxorubicin and sildenafil in killing PC-3 prostate cancer
cells in vitro is intriguing. However, it also raises concerns regarding the possibility of
potentiating the side effects of doxorubicin in non-cardiac cells where cell turnover is
considered a normal physiological process. In the aforementioned chronic mouse model of
used in our investigations, no evidence of potentiation of doxorubicin toxicity in noncardiac cells was observed. Although not investigated in our model, the addition of
sildenafil in patients undergoing chemotherapy with doxorubicin may lead to an increase
in doxorubicin-induced toxicity in hematopoietic stem cells. This could prove fatal during
the induction phase of chemotherapy. Moreover, it may prolong the time that patients
remain neutropenic, thereby exposing them to the additional risk of opportunistic
infections. Further studies are warranted in examining whether this synergistic effect of
sildenafil with doxorubicin is translated to non-neoplastic cells in humans.

75
The mechanism responsible for the synergy of sildenafil in the presence of doxorubicin in
PC-3 prostate cells in vitro is not fully explicable. However, numerous studies using PC-3
cell lines in examining mechanisms of chemoresistance have elucidated several intriguing
hypotheses—many implicating NO as a key mediator in chemosensitization [114-119].
Moreover, many cancer cells develop chemoresistance by overexpressing Bcl-2 and
Bcl-XL, key mediators of apoptosis under the transcriptional regulation of NF-)B [115].
In fact, Huerta-Yepez et al [115] demonstrated the ability of NO donors in down regulating
the expression of Bcl-XL via inhibition of NF-)B activity resulting in the sensitization of
cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). This
ultimately resulted in activation of the mitochondrial pathway of apoptotic cell death.

Furthermore, there is evidence suggesting that suppression of endogenous nitric oxide may
play a key role in hypoxia-induced chemoresistance [119]. Moreover, it has been
demonstrated that hypoxia inducible factor (HIF-1) DNA binding is inhibited by NO in the
presence of hypoxia [118]. In addition, NO has also been demonstrated to inhibit HIF-1$
accumulation in cells under hypoxic conditions [116]. It is therefore not surprising that
PC-3 cells contain all three well-known isoforms of nitric oxide synthase (NOS): eNOS,
iNOS, and nNOS [115].
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In another study by Frederiksen et al [116], exposure of hypoxia to human breast
carcinoma cells resulted in decreased endogenous cGMP, further implicating the role of
NO in chemoresistance. In fact, in a follow-up study, Frederiksen et al provided further
support implicating that administration of low concentrations of NO mimetic agents can
prevent acquired drug resistance in PC-3 prostate cancer cells to doxorubicin [114].

In the present studies illustrating the synergistic effect of sildenafil in doxorubicin-induced
antineoplastic action in PC-3 cells, it is plausible that the inhibition of PDE-5, maintains or
upregulates production of NO to physiological levels thereby “sensitizing” this cancer cell
line to doxorubicin-induced cell death. Further studies will help unravel this conundrum
and provide a better understanding of the role of PDE-inhibitors in the pathophysiology of
cell signaling mechanisms involved in the proliferation of many neoplastic diseases.

Future Investigations
Further studies aimed at attenuating the detrimental effects leading to chronic doxorubicin
cardiomyopathy should be investigated. Some of the potential targets include the
examination of the transcription factors, heat shock factor-1 and GATA-4, in addition to
heat shock proteins and their relationship with cGMP/sGC in cardiomyocytes.

An early event in the cardiotoxic effect of the antitumor drug doxorubicin is GATA-4
depletion, which in turn causes cardiomyocyte apoptosis. Studies by Aries et al [110]
indicate that the transcription factor GATA-4 is antiapoptotic and may be vital for the
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adaptive stress response of the adult heart. As such, the ability to regulate the genes
responsible for apoptosis in the heart via transcription factor modulation offers promise in
the area of heart failure [Figure 21]

The transcription factors GATA-4 and GATA-6 regulate cardiomyocyte hypertrophy in
vitro and in vivo. Recent studies have shown that GATA-4 might also play a role in
survival of adult cardiac myocytes [110,111]. This transcription factor may potentially
regulate pathophysiological conditions such as myocardial ischemia-reperfusion injury,
ischemic preconditioning, and environmental and drug-induced cardiomyopathies where
apoptosis and survival of cardiac myocytes play an essential role. [112]

Additionally, because of the protective effects of the anti-apoptotic protein, Bcl-2, in
preventing doxorubicin-induced cardiomyopathy as demonstrated in vivo [113], it would
be intriguing to ascertain the effect of PDE-5 inhibition in preserving the DNA-binding
activity of GATA-4 and its subsequent ability to preserve basal levels of Bcl-2 following
treatment with doxorubicin. Studying the transcription and phosphorylation of GATA-4 in
vivo can accomplish this.

Moreover, further investigations are warranted that may lead to a better understanding of
the role and significance of PDE-5 localization in cardiomyocytes in vivo and its
relationship to subsequent contractile dysfunction. PDE-5 expression in mouse
cardiomyocytes has previously been demonstrated in our laboratory by Das et al.
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Moreover, Takimoto et al [112] have also demonstrated PDE-5 expression in frozen
sections from adult NOS3 (–/–) mice and their wild-type counterparts. Furthermore, the
study by Takimoto et al suggests that the effects of cGMP on PKG-1 activation is
dependent on z-band localization of PDE-5A, thus enabling modulation of PKA and
subsequent calcium-induced contractility by sildenafil. Moreover, they suggest that acute
NOS3 inhibition removes the critical substrate to the PDE-5A complex and thus eliminates
the antiadrenergic effect of sildenafil. In fact, they infer that chronic NOS3 inhibition or
the use of NOS3 (–/–) mice results in the loss of PDE-5A from the z-band, resulting in the
elimination of sildenafil’s effectiveness in maintaining contractility even in the presence of
exogenous NO. Although intriguing, their rationale for PDE-5A localization to the z-band
is not entirely complete. In recent studies by Fisher [Appendix B, C], clear evidence exists
demonstrating the loss of PDE-5A expression and lack of localization at the z-band in
frozen sections from doxorubicin-only treated mice at 8-weeks post-treatment (total
cumulative dose= 15mg/kg IP). It is plausible that decreased contractility from desmin
disruption subsequently results in the inability of PDE-5A from localizing to the z-band.
Moreover, the ability of caspase-3 in cleavage of desmin at the z-band may be interrelated
to the inability of PDE-5A in locating to the z-band.

One hypothesis that requires further investigation is that PDE-5A localization to the z-band
is associated with protection of desmin cleavage by activated caspase-3. Because NO is
known to inactivate caspase-3 via reversible binding of NO to the active cysteine residue
on the large subunit via s-nitrosylation, it is plausible to that maintaining myofibrillar
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integrity and contractile function at the z-band is coordinated through PDE-5A inhibition
with subsequent physiological available “pools” of NO that are available to inactivate the
detrimental actions of active caspase-3 on myofibrillar disruption of intermediate
filaments.
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Figure 21. Potential targets for further investigation on the molecular mechanisms of
doxorubicin-induced cardiotoxicity.
& 2005 Patrick W. Fisher, DO, PhD
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Appendix A

Confocal microscopic image illustrating desmin distribution (green) and DAPI-stained
nuclei (blue) in a cryosection from a mouse left ventricle at 8 weeks post treatment with
doxorubicin [Total Cumulative dose= 15mg/kg IP]).
& 2005 Patrick W. Fisher, DO, PhD.
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Appendix B

Confocal microscopic image of cryosection from a mouse left ventricle, demonstrating
colocalization of desmin (green) with PDE-5A (red)--in a doxorubicin-only treated animal
8 weeks post treatment (Total cumulative dose = 15 mg/kg IP). Nuclei are stained blue
with DAPI. * Desmin disruption; PDE-5A localization (arrows).
& 2005 Patrick W. Fisher, DO, PhD.

Appendix C

A

B

A, Confocal microscopic image of cryosection from a mouse left ventricle,
demonstrating colocalization of desmin (green) with PDE-5A (red)--in a doxorubicinonly treated animal 8 weeks post treatment (Total cumulative dose = 15 mg/kg IP).
Nuclei are stained blue with DAPI. B, Same image without desmin fluorescence; only
PDE-5A and DAPI-stained nuclei are visible. * Desmin disruption; PDE-5A localization
(arrows). & 2005 Patrick W. Fisher, DO, PhD.
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Appendix D

A

B

D

E

C

Confocal microscopic image of cryosection from a mouse left ventricle in a
doxorubicin-only treated animal 8 weeks post treatment (Total cumulative dose = 15
mg/kg IP), demonstrating PDE-5A (red), A; Phase image, B; desmin (green), C; Nuclei
stained with DAPI (blue), D; and merged image of all three fluorophores, E.
& 2005 Patrick W. Fisher, DO, PhD.
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•
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•
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•
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